Compounding bevacizumab for intravitreal injection: does USP always apply?

Journal article

Peer reviewed

Gary Shienbaum and Harry W Flynn, Jr

Retina (Philadelphia, Pa.), Vol.33(9), pp.1733-1734

2013-10

PMID: 23851633

Abstract

Pharmacopoeias as Topic - standards

Chemistry, Pharmaceutical - methods

Intravitreal Injections

Drug Compounding - methods

United States

Humans

Drug Compounding - standards

Vascular Endothelial Growth Factor A - antagonists & inhibitors

Bevacizumab

Angiogenesis Inhibitors - administration & dosage

Antibodies, Monoclonal, Humanized - administration & dosage

Chemistry, Pharmaceutical - standards

Angiogenesis Inhibitors - chemistry

Antibodies, Monoclonal, Humanized - chemistry

20 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.36 Ophthalmology; 1.36.383 Diabetic Retinopathy
Web Of Science research areas: Ophthalmology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Compounding bevacizumab for intravitreal injection: does USP always apply?
Creators: Gary Shienbaum - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
Harry W Flynn, Jr
Publication Details: Retina (Philadelphia, Pa.), Vol.33(9), pp.1733-1734
Language: English
Resource Type: Journal article
PMID: 23851633
Record Identifier: 991031599325002976